Enlivex Therapeutics
CompanyIsrael
Enlivex Therapeutics develops one asset, in phase 2 (Allocetra in primary knee osteoarthritis). Mostly cell therapy acting on inflammation; based in Israel.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- US$212m
- 1
- Trial
- 1
- Signal
Pipeline
1Apoptotic donor cells promote macrophage reprogramming to resolve inflammation and restore immune homeostasis.
Phase 2, Cell therapy, Inflammation, primary knee osteoarthritis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Funding rounds and grants1
- Signals3
- Similar companies6